While trametinib looks promising for improving patient survival from BRAF mutant melanoma [11], a majority of patients with the NRAS mutation do not respond to MEKi-based therapy alone [12]; only 28% of patients with NRAS-mutated melanoma achieve a stable disease with trametinib treatment [13]. The gene discussed is BRAF; the disease is melanoma.